Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Abstract 2667: Trial in progress: Phase 1 study of BI 1823911, an irreversible KRAS^G12C inhibitor targeting KRAS in its GDP-loaded state, as monotherapy and in combination with the pan-KRAS SOS1 inhibitor BI 1701963 in solid tumors expressing KRAS^G12C mutation

Irene C. Waizenegger, Hengyu Lu, Claus Thamer, Fabio Savarese, Daniel Gerlach, Dorothea Rudolph, Christopher P. Vellano, Marcelo Marotti, John Heymach, Scott Kopetz, Timothy P. Heffernan, Joseph R. Marszalek, Mark P. Petronczki, Marco H. Hofmann, Norbert Kraut

Cancer Res (2022) 82 (12_Supplement): 2667.

https://doi.org/10.1158/1538-7445.AM2022-2667

Published: 15 June 2022

View articletitled, Abstract 2667: Trial in progress: Phase 1 study of BI 1823911, an irreversible KRASG12C inhibitor targeting KRAS in its GDP-loaded state, as monotherapy and in combination with the pan-KRAS SOS1 inhibitor BI 1701963 in solid tumors expressing KRASG12C mutation

Journal Articles

Abstract CT210: Trial in Process: Phase 1 studies of BI 1701963, a SOS1::KRAS Inhibitor, in combination with MEK inhibitors, irreversible KRASG12C inhibitors or irinotecan.

Marco H. Hofmann, Hengyu Lu, Ulrich Duenzinger, Daniel Gerlach, Francesca Trapani, Annette A. Machado, Joseph R. Daniele, Irene Waizenegger, Michael Gmachl, Dorothea Rudolph, Christopher P. Vellano, Marcelo Marotti, Vitomir Vucenovic, Timothy P. Heffernan, Joseph R. Marszalek, Mark P. Petronczki, Norbert Kraut

Cancer Res (2021) 81 (13_Supplement): CT210.

https://doi.org/10.1158/1538-7445.AM2021-CT210

Published: 01 July 2021

View articletitled, Abstract CT210: Trial in Process: Phase 1 studies of BI 1701963, a SOS1::KRAS Inhibitor, in combination with MEK inhibitors, irreversible KRASG12C inhibitors or irinotecan.

Journal Articles

Abstract 1271: In vitro and in vivo characterization of BI 1823911 - a novel KRAS^G12C selective small molecule inhibitor

Cancer Res (2021) 81 (13_Supplement): 1271.

https://doi.org/10.1158/1538-7445.AM2021-1271

Published: 01 July 2021

View articletitled, Abstract 1271: In vitro and in vivo characterization of BI 1823911 - a novel KRASG12C selective small molecule inhibitor

Journal Articles

Abstract LB-122: Combinations of SHP2 inhibitor to overcome RAS activation by receptor tyrosine kinases in response to ERK inhibition

Huaixiang Hao, Chen Liu, Hongyun Wang, Hengyu Lu, Scott Delach, Matthew LaMarche, Jeffrey Engelman, Peter Hammerman, Giordano Caponigro, Susan Moody, Morvarid Mohseni

Cancer Res (2020) 80 (16_Supplement): LB-122.

https://doi.org/10.1158/1538-7445.AM2020-LB-122

Published: 15 August 2020

View articletitled, Abstract LB-122: Combinations of SHP2 inhibitor to overcome RAS activation by receptor tyrosine kinases in response to ERK inhibition

Journal Articles

Abstract LB-259: FGFR- and EGFR-driven SHP2 activation displays differential sensitivity to allosteric SHP2 inhibition

Huaixiang Hao, Hengyu Lu, Chen Liu, Matthew LaMarche, Jeffrey A. Engelman, Peter S. Hammerman, Giordano Caponigro

Cancer Res (2019) 79 (13_Supplement): LB-259.

https://doi.org/10.1158/1538-7445.AM2019-LB-259

Published: 01 July 2019

View articletitled, Abstract LB-259: FGFR- and EGFR-driven SHP2 activation displays differential sensitivity to allosteric SHP2 inhibition

Journal Articles

Abstract 954: SHP2 inhibition overcomes RTK-mediated pathway reactivation in KRAS mutant tumors treated with MEK inhibitors

Hengyu Lu, Chen Liu, Roberto Velazquez, Hongyun Wang, Lukas M. Dunkl, Malika Kazic-Legueux, Anne Haberkorn, Eric Billy, Eusebio Manchado, Saskia M. Brachmann, Susan Moody, Jeffrey A. Engelman, Peter S. Hammerman, Giordano Caponigro, Morvarid Mohseni, Huaixiang Hao

Cancer Res (2019) 79 (13_Supplement): 954.

https://doi.org/10.1158/1538-7445.AM2019-954

Published: 01 July 2019

View articletitled, Abstract 954: SHP2 inhibition overcomes RTK-mediated pathway reactivation in KRAS mutant tumors treated with MEK inhibitors

Journal Articles

Abstract 2808: Simultaneous inhibition of SHP2 phosphatase at two allosteric sites

Cancer Res (2018) 78 (13_Supplement): 2808.

https://doi.org/10.1158/1538-7445.AM2018-2808

Published: 01 July 2018

View articletitled, Abstract 2808: Simultaneous inhibition of SHP2 phosphatase at two allosteric sites

Journal Articles

Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer

Hengyu Lu, Nicole Villafane, Turgut Dogruluk, Caitlin L. Grzeskowiak, Kathleen Kong, Yiu Huen Tsang, Oksana Zagorodna, Angeliki Pantazi, Lixing Yang, Nicholas J. Neill, Young Won Kim, Chad J. Creighton, Roel G. Verhaak, Gordon B. Mills, Peter J. Park, Raju Kucherlapati, Kenneth L. Scott

Cancer Res (2017) 77 (13): 3502–3512.

https://doi.org/10.1158/0008-5472.CAN-16-2745

Published: 02 July 2017

View articletitled, Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer

Includes: Supplementary data

Journal Articles

Abstract 1099: High-throughput engineering and functional annotation of cancer fusion genes

Hengyu Lu, Angeliki Pantazi, Turgut Dogruluk, Armel Dogruluk, Chad Creighton, Gordon B. Mills, Raju Kucherlapati, Kenneth L. Scott

Cancer Res (2015) 75 (15_Supplement): 1099.

https://doi.org/10.1158/1538-7445.AM2015-1099

Published: 01 August 2015

View articletitled, Abstract 1099: High-throughput engineering and functional annotation of cancer fusion genes

Journal Articles

Abstract B106: Personalized functional screens for gene drivers of pancreatic cancer

Yiu Huen Tsang, Turgut Dogruluk, Hengyu Lu, Rosalba Minelli, Nikitha Nair, Marie-Claude Gingras, Agda Karina Eterovic, Gordon Mills, Kenneth Scott

Cancer Res (2015) 75 (13_Supplement): B106.

https://doi.org/10.1158/1538-7445.PANCA2014-B106

Published: 30 June 2015

View articletitled, Abstract B106: Personalized functional screens for gene drivers of pancreatic cancer

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract 2667: Trial in progress: Phase 1 study of BI 1823911, an irreversible KRAS^G12C inhibitor targeting KRAS in its GDP-loaded state, as monotherapy and in combination with the pan-KRAS SOS1 inhibitor BI 1701963 in solid tumors expressing KRAS^G12C mutation

Abstract CT210: Trial in Process: Phase 1 studies of BI 1701963, a SOS1::KRAS Inhibitor, in combination with MEK inhibitors, irreversible KRASG12C inhibitors or irinotecan.

Abstract 1271: In vitro and in vivo characterization of BI 1823911 - a novel KRAS^G12C selective small molecule inhibitor

Abstract LB-122: Combinations of SHP2 inhibitor to overcome RAS activation by receptor tyrosine kinases in response to ERK inhibition

Abstract LB-259: FGFR- and EGFR-driven SHP2 activation displays differential sensitivity to allosteric SHP2 inhibition

Abstract 954: SHP2 inhibition overcomes RTK-mediated pathway reactivation in KRAS mutant tumors treated with MEK inhibitors

Abstract 2808: Simultaneous inhibition of SHP2 phosphatase at two allosteric sites

Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer

Abstract 1099: High-throughput engineering and functional annotation of cancer fusion genes

Abstract B106: Personalized functional screens for gene drivers of pancreatic cancer

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only